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 Abstract: 
 
New strategies to combat complex human disease require systems approaches 
to biology that integrate experiments from cell lines, primary tissues and model 
organisms. We have developed Pathprint, a functional approach that compares 
gene expression profiles in a set of pathways, networks and transcriptionally-
regulated targets. It can be applied universally to gene expression profiles across 
species. Integration of large-scale profiling methods and curation of the public 
repository overcomes platform, species and batch effects to yield a standard 
measure of functional distance between experiments. We show that Pathprints 
combine mouse and human blood developmental lineage, and develop new 
prognostic indicators in Acute Myeloid Leukemia. The code and resources are 
available at http://compbio.sph.harvard.edu/hidelab/pathprint.  
 
Background: 
 
Complex human diseases arise from perturbations of the cellular system [1]. 
Defining these changes from a systems biology perspective provides the 
opportunity to relate the function of genes, pathways and processes. The ability 
to compare experiments across model organisms and humans directly impacts 
our capacity to determine the basis of disease [2-4] and the importance of cross-
species data analysis has been well illustrated: human disease genes have been 
identified by large scale meta-analysis of conserved human-mouse co-
expression [5], gene-based cross-species distance metrics have highlighted 
diseases that activate similar human and mouse pathways [6], and oncogenenic 
expression signatures have been prioritized by comparing human cancer and 
mouse model expression profiles [7-9]. Gene expression provides the most 
extensive resource to profile functional changes, and the opportunity for wide-
scale meta analyses has been made possible by the development of public data 
repositories such as the National Center for Biotechnology Information Gene 
Expression Omnibus (GEO) [10] and the European Bioinformatics Institute 
ArrayExpress [11]. Cross-study analysis and integration is an area of highly 
active research, however, most gene-based approaches are confounded by the 
challenge of comparing gene activity between different platforms and species. 
Consistent and scalable methods for combining these data are now required so 
that researchers can perform comprehensive integration of prior knowledge with 
new experiments, identify consistent signals, compare heterogeneous data, and 
validate hypotheses. 
 
Methods for cross-study integration of gene expression data have tended to 
focus on differential expression in well-matched control and experimental 
samples [12], as approaches based on correlation or absolute profiles [13] are 
dominated by lab and platform variability in cross-study analyses [14]. The ability 
to leverage public data to address platform-effects has been demonstrated most 
recently by the Gene-Expression Barcode, and Gene Expression Commons, 
both of which define absolute gene expression scores based on a background distribution [15, 16]. By virtue of their reliance on gene level comparisons, these 
compelling simplifying approaches are restricted to selected platforms and so do 
not address global comparison of biological function across experiments and 
species. 
 
We have sought to develop a new, functional-based, approach for comparing 
profiles that can truly scale across the diversity of available experiments, 
platforms and species. Expression of biological functions across batches and 
divergent expression platforms shows higher concordance than genes [17], and  
assigning genes to pathways [18-20] or ontologies [21] is effective for revealing 
phenotype associations [22-25], cross-platform integration [14], and specifying 
disease subgroups [26]. On this basis, we have developed Pathprint, a 
global pathway activation map spanning 6 species and 31 array technologies that 
represents expression profiles as a ternary score (under-expressed {-1}, 
intermediately-expressed {0}, over-expressed {+1}) in a set of 633 pathways, 
networks and transcriptionally-regulated targets. The method leverages a static 
background built from public data repositories, integrating pathway annotation 
and prediction with large-scale profiling. 
 
Pathprint provides a quantitative definition of cellular phenotype, and a functional 
distance between all experiments based on their global pathway activity. It 
presents a significant methodological advance over single-study, relative 
enrichment methods such as Gene Set Enrichment Analysis (GSEA) [27] and 
existing gene-based methods for comparison between platforms and species. 
Pathprinting provides a robust framework for large-scale meta-analysis of clinical 
data, and allows phylogenetic reconstruction of developmental lineages from a 
functional perspective. We demonstrate the use of Pathprinting for retrieval of 
functionally matched samples from cross platform expression databases, 
reconstruction of the blood developmental lineage across species, and the 
integration of data from mouse experiments, human samples, and clinical studies 
to develop new prognostic indicators and drug targets in Acute Myeloid 
Leukemia. 
 
Methods: 
The pipeline to create a Pathprint of an array is shown in Figure 1. A score of 0 in 
the final Pathprint vector represents pathway expression at a similar level to the 
majority of arrays of the same platform in the GEO database; scores of 1 and -1 
reflect significantly high and low expression respectively. Below we describe the 
individual steps used to construct the method. 
 
Expression data for building pathway background distributions 
A list of arrays from 31 of the most highly represented one-channel gene 
expression platforms in GEO that profiled Homo sapiens, Mus musculus, Rattus 
norvegicus, Danio rerio, Drosophila melanogaster and Caenorhabditis elegans 
was compiled (please see Additional file 1) and the normalized expression tables 
retrieved, all normalization methods were accepted. After discarding incomplete records, this list contained 176,971 arrays. It was necessary to restrict the 
platform coverage to one-channel arrays as two channel arrays provide the 
relative expression of genes between test and control samples, hindering direct 
comparison of the test sample between experiments when the control sample 
differs. The expression data were mapped to Entrez Gene IDs using 
systematically updated annotations from AILUN [28]. Multiple probes were 
merged to unique Entrez Gene IDs by the mean expression level. It should be 
noted that although the mean expression level will produce stable gene 
expression values ﾠit ﾠalso ﾠ‘averages ﾠout’ ﾠthe ﾠeffects ﾠof ﾠalternative promoter usage 
and splice variants. Tissue specific splicing has been recognized as an important 
factor in defining cellular function [29], however at the present time, there is 
insufficient data to consistently map individual splice variants to pathways. 
 
Pathway databases 
Canonical pathway gene sets were compiled from Reactome [18], Wikipathways 
[20] and KEGG [19], which were chosen as they include pathways relating to 
metabolism, signaling, cellular processes, and disease. For the major signaling 
pathways experimentally derived transcriptionally up and down regulated gene 
sets were obtained from Netpath [30]. The pathways provide structured 
relationships between genes, unlike ontologies such as GO [21] that define 
relationships between but not within terms. 
 
Static Modules 
Pathprint is built to leverage expertly curated biological knowledge found in 
canonical pathway databases in a systematic framework. This approach provides 
a consistent biological annotation of datasets in terms that are well understood 
by the community. However, a uniquely pathway-centric approach would 
introduce an inherent curation bias towards well-studied genes and processes. 
Therefore, we have supplemented the curated pathways with non-curated 
sources of interactions by including highly connected modules from a functional 
interaction ﾠnetwork, ﾠtermed ﾠ‘static ﾠmodules’. ﾠThis ﾠfunctional ﾠinteraction ﾠnetwork ﾠ
was constructed by extending curated pathways with non-curated sources of 
information, including protein-protein interactions, gene co-expression, protein 
domain interaction, Gene Ontology (GO) annotations and text-mined protein 
interactions. The final functional-interaction network contains 181706 interactions 
between 9452 genes [31], representing close to 50% of the total human 
proteome. A Markov Cluster Algorithm was applied to decompose the network, 
yielding ﾠ144 ﾠclosely ﾠrelated ﾠfunctional ﾠinteraction ﾠclusters, ﾠ‘static ﾠmodules’, ﾠ
ranging from 10 to 743 nodes. Each cluster was named according to the member 
gene with the highest interaction degree. The modules cover 6458 genes, 1542 
of which are not represented in any of the pathway databases. These static 
modules offer the opportunity to examine the activity of less studied or annotated 
biological processes, and also to compare their activity to that of the canonical 
pathways. To provide biological context for the static modules the top GO terms 
associated with all the pathways have been compiled (please see Additional file 
2).  
Compiling cross species gene sets  
M. musculus, R. norvegicus, D. rerio, D. melanogaster and C. elegans gene sets 
were inferred using homology based on the HomoloGene database [32]. 
HomoloGene uses pairwise gene comparison combined with a guide tree and 
gene neighborhood conservation. HomoloGene was selected as, when 
compared to alternative inference methods, it provides a better functional proxy 
and higher specificity for the resolution of shared cellular ontogeny, albeit with 
lower overall coverage [33]. 
 
Summary of the Pathprint gene sets  
All of the modules and pathways were converted to flat gene sets, so intra-
pathway gene-level interaction data are not used. Combined, the canonical 
pathways, downstream targets, and static modules total 633 human gene sets. 
The gene membership of these sets is described in Table 1, within the R 
package Pathprint, and on the Pathprint website, for the number of genes 
overlapping between each of the data sources please see Additional file 3. 
Specific pathway sub-subsets may also be used in individual analyses.  
 
Calculating pathway expression 
Genes were ranked by expression level, from 1 (low expression) to N (high 
expression), where N is the total number of genes in the array. For a pathway, P 
of size k, represented in an array by genes G1, G2…Gn, the pathway expression 
score, En(P), is defined by the mean squared-rank, 
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Where Ri is the rank of gene Gi in a pathway containing n genes. Rank 
normalizations provide robust summary statistics to calculate pathway 
expression scores [6, 13] that can be applied across all technologies, and does 
not depend on the dynamic range of an array. The mean squared rank was used 
based on a survey of statistical approaches for gene set analysis [34] and out-
performed other summary statistics in a series of classification benchmarks 
based on tissue-specific pathway expression (see benchmarking section below). 
 
Normalization and probability of expression (POE) 
When comparing gene set expression scores between experiments it is essential 
to assess the expression against a suitable null hypothesis [35]. In this case, 
comparing the expression of a gene set in one array to its expression in all other 
arrays, i.e. sample permutation, is required to account for the internal gene 
expression correlation structure within gene sets, expected to be particularly high 
within pathways [36]. For each gene set, the expression score was normalized 
against a background built using all arrays of the same platform type. This is the 
first study comparing database-wide gene set expression and the expected 
distribution scores is not known. We adopted a similar approach to the Gene Expression Barcode [15] that estimates which genes are expressed and which 
are unexpressed in data from single microarrays. The Gene Expression Barcode 
converts gene expression levels to binary scores based on a static background 
distribution built from public expression data for 3 distinct platforms. Here, we 
constructed static pathway expression background distributions for each pathway 
across 31 platforms in GEO [10]. Each of these distributions was then fit to two-
component uniform-normal mixture model [37]. The normal component 
represents the core distribution of pathway expression scores for a particular 
pathway, i.e. not significantly high or low expression. The uniform component 
represents outlying pathway expression due to significantly high or low 
expression. A signed Probability of Expression (POE) can be calculated 
representing the probability that a pathway expression score belongs the uniform 
component of the fitted mixture model. We took advantage of the increase in 
computation speed afforded by the expectation-maximization implementation of 
POE in the R package metaArray [38]. 
 
Application of a ternary threshold 
High/low thresholds [15], or filters with weight vectors approaching the 
thresholding limit [6], operate as an effective noise filter to remove uninformative 
signal variation. POE values were converted to a ternary score by the 
transformation 
 
 
Fi 1       T  POEi
       0     -T  POEi T
     1      POEi  T  
 
Where POEi (i = 1,2...n) represents the POE for gene set i, T is the threshold and 
the Fi are components of the Pathprint vector. Selection of the threshold, T, is of 
vital importance as this directly modulates the sensitivity and specificity at which 
gene sets are scored as significant. Large values of T - high stringency - is 
appropriate for gene expression [15]. Small values of T - low stringency - 
increase the weighting of subtle differences in expression, and may be required 
to discriminate arrays at the pathway level, where the coordinated effects of 
multiple genes are under consideration. The threshold was optimized by 
combining multiple benchmarks (see below). Thresholding improves sample 
clustering (see below), provides a read-out for sample annotation, and simplifies 
quantification of sample relationships.  
 
Constructing consensus pathprints 
To summarize the activity of a group of pathprints we define the consensus score 
for each pathway as  
 
 
Ci 1   i  t
1   i  t 
 Where ﾠμi is the mean score for pathway i across the group of pathprints, and t is 
a consensus threshold value. The consensus pathprint is the vector constructed 
by calculating the consensus score for each pathway, representing the 
consistently significantly expressed pathways across the group. The rationale 
behind introducing a threshold is to associate a set of pathways with a 
phenotype, and so provide a discrete functional representation of a cell type 
based on a collection of pathprints. 
  
Defining distance between pathprints 
A functional distance between experiments is defined as the distance between 
two pathprint vectors. We define the distance by the Manhattan distance, 
providing a simple readout for the number of pathway scores that differ between 
two samples. We define the distance from a consensus pathprint to any other 
pathprint by the Manhattan distance between the subset of the pathprint vectors 
that contain only the pathways for which the consensus pathprint is non-zero. 
This ensures that only differences in the consistently expressed pathways that 
make up the consensus pathprint are considered. 
 
Optimizing threshold value 
The threshold value was optimized using cross-platform, cross-species gene 
expression data from a panel of human and mouse tissue samples [15] and an 
independent dataset profiling brain sub-regions in human, mouse and rat [39]. 
Four approaches were used to determine the optimum threshold. 
i) Cross-validation 
The data sets were divided into 5 subsets of equal, or approximately equal, size. 
One of the subsets (the test set) was omitted and mean pathprints were 
calculated for each tissue from the remaining samples (the training set). Next, the 
samples in the test set were assigned to the tissue with the closest mean tissue 
pathprint in the training set by Euclidean or Manhattan distance (both yielded 
similar results). An error rate was calculated by comparing these assignments to 
the known annotations. This was repeated, omitting each of the subsets in turn, 
to obtain a mean error rate. The cross validation procedure was performed 10 
times for each threshold value to estimate the mean and standard deviation of 
the error rate. The standard deviation was small relative to the change in mean 
error rate over the thresholds and so this number of repetitions was deemed 
sufficient (Additional file 4). The procedure was also performed as a leave-one-
out cross validation, equivalent to dividing the data into a number of subsets 
equal to the same number of samples, with similar results. 
 
ii) Cluster validity (intra- vs. inter-tissue distance and principle component 
analysis) 
Cluster validity was determined by the ratio of the intra- to inter-tissue variance, 
where variance was defined as sum of the squared Euclidean distance between 
each sample and the mean pathprint for each tissue. A lower ratio indicates 
tighter clustering within tissues and/or better separation of the tissue type 
clusters. The clusters formed by pathprints had an intra/inter cluster distance ratio of 0.63, compared to 1.26 for the Barcode and 0.92 for Spearman 
correlation (Additional file 4). 
 
iii) Retrieval: Precision-Recall of cross-species tissue data 
The combined human and mouse dataset was ranked by distance from each 
sample (Manhattan, Euclidean or Spearman correlation). These ordered retrieval 
lists were used to calculate average interpolated precision-recall curves at a 
range of threshold values. Decreasing the stringency of the threshold initially 
improved performance but at thresholds below 0.001 the difference became less 
significant, summarized by the plot of mean average precision (Additional file 4). 
Pathprinting improves the performance of tissue retrieval across species over 
gene expression measurements (both Barcode and Spearman correlation) and 
results obtained with randomly constructed gene sets (Figure 2). Pathway 
expression scores based on the mean squared-rank out-performed the mean 
rank, as assessed by precision-recall curves for the tissue-species data. In 
addition, an identical analysis pipeline was also constructed using the GSEA 
algorithm, as applied to single samples [25], as the initial step, in place of the 
mean squared rank. It was found that the enrichment scores were highly 
correlated and yielded no significant improvements in precision or recall. There 
was also a much greater computational burden associated with running GSEA on 
180,000 arrays compared to the mean squared rank. 
 
iv) Comparison to randomly constructed gene sets 
A Pathprint ﾠbased ﾠon ﾠ‘random’ ﾠgene ﾠsets ﾠwas ﾠconstructed ﾠto ﾠtest ﾠwhether ﾠthe ﾠ
‘expert’ ﾠknowledge ﾠcontained ﾠwithin ﾠthe ﾠpathways ﾠand ﾠmodules ﾠcontribute ﾠto ﾠthe ﾠ
success of the Pathprint over and above the effect of simply reducing the 
dimensionality of the data. These random gene sets contained genes sampled 
without replacement from the genes used in the original pathways and retained 
the size distribution of the original pathway list. The precision-recall curves for 
Pathprint based on random gene sets (Figure 2, Additional file 4), demonstrate 
inferior performance compared to Pathprint. This is especially pronounced at 
stringent thresholds. At less stringent thresholds, the difference between the 
curves is smaller, implying that both the reduction in data dimensionality and the 
integration of biological knowledge contribute to the effectiveness of Pathprint. 
 
A threshold value of 0.001 was chosen on the basis that it performed optimally 
across the majority of the performance measures. It is interesting to note that a 
highly stringent threshold, ~0.9, did not perform well in cross-validation but 
yielded good results for the precision-recall and cluster validity tests, and 
produced the greatest difference in performance compared to the equivalently 
thresholded random genesets. These results show that moderate pathway 
expression levels best characterize samples, but the most highly expressed 
pathway expression scores are also informative. Further work is required to 
determine whether combining more than one thresholding regimen would be 
beneficial. 
 Phenotype matching using the GEO database 
Any ﾠset ﾠof ﾠarrays ﾠcan ﾠbe ﾠused ﾠas ﾠa ﾠ‘seed’ ﾠto ﾠconstruct ﾠa ﾠconsensus ﾠpathprint ﾠ
profile representing the commonly expressed functions of the set, e.g. tissue-
specific arrays (Figure 2). The distance of every array in the GEO pathprint 
collection then can be measured to produce a table of GEO samples, ordered 
according to their phenotypic similarity to the seed set, i.e. a ranked list of 
retrieved samples (please see Additional file 5). 
 
Distribution of distances 
In considering the distribution of distances from a consensus pathprint, a major 
problem is how to assign a measure of significance. This is particularly important 
if it is necessary to impose a cutoff at which to evaluate retrieved results. 
Calculating significance based on the distribution of pathprint scores across the 
full GEO database is complicated as a) each pathway has a different distribution 
of ternary scores and b) the pathways scores are known to be correlated. An 
alternative strategy is to use the distribution of the database to define a 
background distribution, based on the following assumption. Firstly, that there are 
two distinct populations, a small number of closely matched and a large number 
of non-matched samples, and secondly that the distances of the non-matched 
samples are normally distributed. The estimated distribution of the non-matched 
samples is derived from the inter-quartile range of the full distribution. The 
significance with which an array is matched with a pathprint, or with a consensus 
pathprint, is then calculated using the p-value based on the normal distribution 
function based on this estimated distribution. This approach is clearly an over-
simplification and a more complete significance model will form the basis of 
further study. We expect a large number of the samples contained in GEO to be 
disease related, representative of a research focus bias inherent in the scientific 
literature, and so we are aware that the underlying distribution could be 
multimodal due to perturbed transcriptional programs and copy number 
variations associated with disease, and specifically cancer cell types. The 
correlation between this estimated p-value and the precision for each of the 6 
tissue samples is shown in Additional file 5. 
 
Phylogenetic analysis 
Pathprints corresponding to hematopoietic gene expression datasets GSE24759 
[40] and GSE6506 [41] were calculated using the Pathprint pipeline. A 
consensus pathprint was constructed for each of cell types using an arbitrarily 
selected threshold of 0.75. Phylogenetic analysis was performed using the R 
package Phangorn [42]. Optimized parsimony and (non-parametric) 
bootstrapped trees were found by nearest neighbor interchange with a cost 
matrix based on the difference between pathprint scores.  
 
Self-renewal signature and survival analysis 
Gene expression data for leukemia stem cell, normal stem cells and progenitor 
cells in mouse and human were obtained from the GEO (GSE24006 and 
GSE3722). Pathprints were calculated for each sample using the Pathprint package in R. Pathways shared by leukemic and normal stem cells that are 
differentially expressed in progenitor cells were identified for the human and 
mouse datasets. The self-renewal signature (SRAS) was defined as the set of 
pathways common to the human and mouse signatures. Gene expression arrays 
and the associated survival data were obtained for 4 clinical studies of acute 
myeloid leukemia from GEO (GSE10358, GSE12417, GSE1159, and 
GSE14468). Pathprints were calculated for each sample in these datasets. 
Survival plots and associated p-values were derived using the Kaplan-Meier 
method by stratifying patient samples into two groups by the sum of their 
pathprint scores across the SRAS pathways. For each dataset the approach was 
repeated 1000 times using random permutations of the pathprint pathways with 
the same number of member pathways as the SRAS set to produce a 
background distribution of p-values against which to compare the SRAS result.  
 
Code and Pathprint R package 
The code and data to process gene expression arrays to pathprints have been 
compiled into the R package Pathprint. Pathprints have also been pre-calculated 
for approximately ~180,000 gene expression profiles from the GEO repository 
and included in the R package, along with their associated metadata to create a 
search-able cross-platform matrix covering 31 platforms and 6 species (please 
see Additional file 1). Future versions of Pathprint will extend the acquisition 
pipeline to encompass the remaining platforms and incorporate data from other 
repositories. The package as well as the complete R code (as Sweave 
documents) required to reproduce the analysis and figures contained within this 
manuscript are available online[43]. 
 
Results and Discussion: 
The ability of pathprints to classify cross-platform and species data was tested on 
a series of tissue specific datasets, and compared to the Gene Expression 
Barcode [15], gene-expression correlation, and a pathprint based on random 
gene sets (Figure 2, Additional file 4). In each test, Pathprint improves sample 
classification, and clusters tissues together across platform and species. The 
biological and technical variation across pathprints in the tissue-specific dataset 
was investigated by principal component analysis (Figure 2c). The first two 
principal components separate most tissue types, irrespective of their originating 
platform and species, with some convolution of the lung and spleen samples. 
Notably, a corresponding plot produced from Gene Expression Barcode data 
clusters samples first by platform and then tissue type (Figure 2d). 
 
A high degree of overlap in gene membership is introduced when combining 
multiple pathway databases. Overlapping gene membership can be due to 
redundancy in the pathway sets, for example different views of the Wnt pathway 
in the Reactome, Wikipathway and KEGG databases, or due to pathways being 
closely biologically related and so sharing a subset of there ﾠgenes, ﾠsuch ﾠas ﾠ‘G1 ﾠ
to ﾠS ﾠcell ﾠcycle ﾠcontrol’ ﾠand ﾠ‘DNA ﾠreplication’. Overlapping genes will result in 
correlation between the gene expression scores of these pathways. In addition to the correlation due to overlapping genes, it is well recognized that pathways do 
not function as discrete elements but are organized into cascades and co-
regulatory networks. We have not attempted to make a quantitative definition of 
the second source of correlation but have tested the effect of correcting for 
overlapping genes by incorporating a pathway covariance matrix to adjust the 
contribution of each gene set using the Mahalanobis distance. The covariance 
matrix was calculated using pathway expression scores from 10,000 randomly 
permuted expression profiles to providing a measure of the covariance due to the 
gene member overlap, without the additional complication of gene-gene 
expression correlations. In the benchmark tests the Mahalanobis distance did not 
improve performance over the simpler Euclidean and Manhattan distances 
(Figure 2b). Accordingly, all pathways, irrespective of size and including 
overlapping gene sets, were retained in the pathprint. No additional correction 
was made as we wish to maximize the utility of the pathprint as a source of 
annotation of samples as well as for sample clustering and organization. Plans to 
include feature selection of gene sets that contribute the most towards 
performance, for example by non-negative matrix factorization are the subject of 
ongoing algorithmic development. 
 
We will now outline a series of case studies demonstrating major applications of 
pathprinting that focus on integrating data from human and mouse. 
 
Tissue-specific pathway profiles 
The consensus pathprints derived from the tissue specific datasets described 
above define consistent functional identities for each tissue, for example skeletal 
muscle expresses myogenesis, liver and kidney express metabolic pathways, 
and brain expresses neuroactive ligand receptors (Figure 2e). To validate these 
tissue-specific pathway combinations, the full GEO matrix of pathprints, 
approximately 180,000 samples, were ranked based on pathprint distance from 
each tissue profile. Originating tissue types were assigned for each GEO sample 
using the metadata in the database allowing validation of the matched samples 
and the construction of precision-recall curves for each tissue. The results 
demonstrate remarkable specificity (Table 2, Additional file 5): the 50 human and 
mouse brain Affymetrix arrays used to build a brain profile retrieved ~8,500 brain 
samples at 95% precision, spanning 4 species (human, mouse, rat and 
zebrafish) and 25 different platforms (from Affymetrix, Illumina and ABI). For 5 of 
6 tissues over 1,000 correctly matched arrays were retrieved at 95% precision. 
Although performance is noticeably worse for the spleen, a high proportion of 
spleen mass is blood, and therefore blood samples, predominantly leukocytes, 
ranked highly in the retrieval list, lowering the observed precision. We tested the 
ability of the brain and liver mouse and human consensus pathprints to retrieve 
samples from each of the other species covered by the pathprint; rat, zebrafish, 
fruit fly and nematode. The top matches for the brain consensus were all brain 
samples for rat and zebrafish, head samples for fruit fly and a more 
heterogeneous set that included neuron samples for nematode. The top samples 
retrieved by the liver consensus were liver in rat and zebrafish, and whole samples for nematode and fruit fly (please see Additional file 6). 
 
Development of a pluripotent pathprint 
The study and characterization of embryonic stem (ES) cells is dominated by 
subjective choices of selection markers. ES cells express consistent 
transcriptional profiles that provide benchmarks for pluripotency [44], however to 
date, it has not been possible to consistently assess ES signatures across all 
available data and platforms and it is becoming increasingly important to provide 
biologically interpretable functional signatures that are robust across a range of 
experimental origins. An ES pathprint was derived from 127 human and mouse 
samples (please see Additional file 7) that includes high expression of known ES-
related functions such as DNA repair, one-carbon metabolism [45] and a network 
centered on SUMO1, the ubiquitin-related modifier thought to target and stabilize 
Oct4 [46]. The profile is a consistent indicator of pluripotency; 90% of the 1,000 
closest pathprint-matched samples in GEO are ES and induced pluripotent stem 
(iPS) cells from 140 different human and mouse studies and 13 platforms (please 
see Additional files 8 and 9). The non-ES/iPS samples retrieved were cancer cell 
lines known to express ES, consistent with the concept that pathways required 
for stem cell specification play fundamental roles in tissue regeneration and 
cancer. Systematically profiling stem cells using pathprints to integrate data from 
mouse models, human primary tissue and clinical studies will resolve the 
contributions of these stem pathways to developing and aberrant systems and 
reveal pathways of clinical relevance. 
 
Integration of the human and mouse hematopoietic lineage 
Mapping cellular lineages has traditionally relied on direct observation, or by 
endogenous or genetically engineered markers. Defining cell types using a 
combination of markers is not always possible, and often the link between marker 
and cellular function is not understood. Hematopoietic differentiation has been 
analyzed in the context of the canonical view of blood lineage using gene 
expression profiles of surface marker purified populations in human [40] and 
mouse [41]. Pathprinting allows a novel pathway-based phylogenetic approach 
for an unsupervised definition of this lineage by maximum-parsimony 
reconstruction using the discrete pathprint states. The reconstruction 
recapitulates the known lineage ontogeny and allows integration of human and 
mouse data, using the common informative pathways (Figure 3, Additional file 
10). The phylogeny resolves the major myeloid and lymphoid branches 
independent of species. Species-specific contributions overcome some cell-type 
groupings, but this is unsurprising as marker selection and immune presentation 
differ between the experiments. A comprehensive survey of mouse immune-cell 
gene expression is in progress [47]. As these and further data becomes 
available, pathprints will allow integration with the existing human and mouse 
ontogenies, providing functional differences, and resolving problems of data 
availability and incomplete lineage coverage.  
 
Self-renewal pathways in acute myeloid leukemia Well-characterized mouse models of acute myeloid leukemia (AML) have been 
used to explore the molecular basis for stem-like behavior of sub-populations of 
leukemia cells [48]. A self-renewal associated gene signature (SRAS) has been 
identified that is activated in both hematopoietic stem cells and leukemia initiating 
cells. An analogous study of human AML has identified a clinically relevant stem-
associated signature expressed in human normal hematopoietic and leukemia 
stem cells [49]. There are only 4 genes common to the published human and 
mouse signatures, and the extent to which the mouse model functionally 
recapitulates the human system is unknown. A pathprint analysis systematically 
extracts and compares the pathways defining stem phenotypes in each of these 
studies, identifying 4 common human and mouse stem-associated pathways. 
The common pathways are translation factors and class B secretin-like GPCRs 
from Wikipathways, and static modules centered on PLCG2 and RAN (Figure 
4a). There is no overlap between these pathways at the gene level. The 
combinatorial clinical relevance of these pathways was tested by calculating 
pathprints for 4 independent clinical studies of gene expression in AML patients 
[50-53]. The patient samples were grouped into high and low expression groups 
by k-means clustering of the sum of their pathprint scores in the common self-
renewal pathways. High scores are associated with poor prognosis in each of the 
studies and is also significant compared to a background of random pathway 
permutations (Figure 4b, Additional file 11). The identification of translation 
factors suggests that modulation of translation might be a therapeutic approach 
in poor-prognosis AML, consistent with studies targeting this process in early 
phase clinical trials [54]. The set of stem cell pathways that are conserved across 
human and mouse have significantly greater clinical relevance than either the 
human or mouse pathways on their own, demonstrating the value of a cross 
species analysis in this case study (Additional file 12). The GPCRs, PLCG2 and 
RAN modules may represent new pathways for clinical investigation; a clear 
relationship between the pathprint score and clinical outcome is observed for the 
PLCG2 module, a tightly connected set of genes involved in signaling and 
metabolism (Figure 4c, Additional file 13). 
 
Conclusions: 
 
The Pathprinting project provides the community with a consistent, functional 
annotation of gene expression across ﾠa ﾠfixed ﾠ‘set’ ﾠof ﾠpathways. It moves beyond 
traditional approaches, resolving the major bottleneck on the road towards 
efficient systems-biology based modeling by addressing the inherent 
experimental and platform biases that confound microarray analyses. 
Pathprinting is now being applied to group the function of datasets within the 
Harvard Stem Cell Institute Stem Cell Commons (stemcellcommons.org) so that 
samples that have similar function can be discovered within stem cell data. A 
cytoscape plugin is also in development as part of the NHLBI Progenitor 
consortium[55] and we have integrated the method into the Stem Cell Discovery 
Engine [56] (SCDE) to provide web-based accessibility. The SCDE is a portal for 
integrated access to tissue and cancer stem cell experimental information and molecular profiling analysis tools via a web-based Galaxy instance. Pathprinting 
is also embedded within the toolbench distribution of Galaxy. We encourage the 
community to employ Pathprinting to communicate functional findings more 
consistently. It is important to note that Pathprinting is effective for use on single 
samples - a sample can easily be pathprinted and ﾠcompared ﾠto ﾠ‘what ﾠis ﾠthere’. ﾠ
This has significant implications for applications in personalized medicine and 
single cell analyses. 
 
The R package Pathprint is provided to calculate pathprints (or continuous 
pathway scores) from expression arrays and pathway enrichments from input 
gene lists. The package also contains a database of approximately 180,000 
pathprints from GEO. The packages, along with Sweave files detailing the 
package usage and analysis in this paper are available online[43]. A 
supplementary package, pathprintTF is also provided, containing a similar 
framework and database to pathprint but built upon protein interaction modules 
centered on transcription factors rather than pathways to enable cross-platform 
comparison of transcriptional control elements. The transcription factor modules 
are based on protein-protein interaction sub-networks centered on a series of 
1022 transcription factors, the package and more details are provided on the 
pathprint website.  
 
The correlation of mRNA expression to protein levels, and also to phenotype, 
depends on a variety of factors such as translation efficiency, mRNA abundance, 
ribosome occupancy, protein abundance and turnover. Gene expression levels 
are a good surrogate for protein levels for housekeeping genes (ribosomal 
proteins, glycolytic enzymes and TCA cycle proteins) but mRNA levels correlate 
less well with protein levels for kinases, proteases, secreted proteins and 
transcription factors, and overall mRNA variability explains approximately 40% of 
the variability in protein levels. Pathprinting establishes a standardized method 
for large-scale quantitative comparisons of cellular function, and any analysis of 
this type depends on the availability of large-scale quantitative genome-wide 
data-sets. Gene expression data repositories are currently the only resource 
expansive enough to address this need. Future versions of the Pathprint will 
extend the value of existing array data by integrating RNA-seq, epigenetic and 
proteomic profiles, providing context for new experiments from the existing body 
of microarray data, and helping resolve the links between regulation and 
expression of cellular function.  
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Tables 
 
Table 1: Summary of gene sets used in pathprint  
   Pathways  Mean size  Median size  Min size  Max size  Total genes  
Reactome  53  153.6  108  11  932  4874 
Wikipathways  173  50.14  33  6  260  3918 
Netpath  36  170.08  83  8  816  3811 
KEGG  227  75.51  55  6  1138  5990 
Static Modules  144  44.9  21  9  733  6458 
All  633  73.53  41  6  1138  10903 
 
Table 2: Pathprint-based retrieval of data from GEO: Arrays retrieved from 
GEO from consensus tissue pathprints at 95% precision. 
 
   Seed Arrays  Correct retrievals  Platforms  Species 
Brain  50  8691  25  4 
Kidney  81  1156  14  3 
Liver  196  4797  22  4 
Lung  142  1735  13  3 
Skeletal muscle  29  2919  18  3 
Spleen  33  179  5  2 
 
 
 
 
Figure Legends 
 
Figure 1: The Pathprint pipeline: Rank-normalized gene expression is mapped 
to pathway expression. A distribution of expression scores across GEO is used 
to produce a probability of expression (POE) for each pathway. A pathprint vector 
is derived by transformation of the signed POE distribution into a ternary score, 
representing pathway activity as significantly under-expressed [-1], 
intermediately-expressed [0], over-expressed [+1]. 
 
Figure 2: Cross-species integration a): Precision-recall within tissue training 
dataset for the pathprint (red, mean average precision 0.90), unthresholded POE 
(dashed, 0.88), random gene sets (black, 0.83), gene-expression barcode (blue, 
0.73), Spearman gene-expression correlation (green, 0.71). (b) Comparison of 
distance metrics: Precision-recall curves for aggregated mouse to human tissue 
data based on a thresholded pathprint build using Euclidean (blue), Manhattan 
(green) and Mahalanobis distances (red). Tissue- vs platform/species-dominated 
clustering: Plots of the two most significant principal components (PC) for (c) the 
pathprint and (d) the gene expression barcode, brain = red, kidney = yellow, liver 
= green, lung = light blue, muscle = dark blue, spleen = pink, Mouse 430A2 = 
circles, Human 133plus2 = diamonds, Human 133A = crosses (e) Functional 
classification of tissues and blood cell types: Hierarchical clustering of consensus 
pathprints for human and mouse tissues on three platforms based on the 
Wikipathway and Reactome pathways that significantly contributing the 
clustering. Colors indicate 1 (red), 0 (white) and -1 (blue)).  
 Figure 3: Functional classification of blood cell types: a) Maximum parsimony 
phylogenetic reconstruction of the hematopoietic lineage using pathprints 
calculated from a) human[40] and b) mouse [41] gene expression experiments. c) 
Combined human-mouse tree based on shared informative pathways that 
resolve trees a) and b) and pathway heatmap. The myeloid (yellow) and 
lymphoid (purple) branches are indicated, dark branches represent agreement 
with the canonical lineage. See Additional file 10 for pathway annotations.  
 
Figure 4: Clinically important Self Renewal Associated Signature in AML: 
a) Pathways differentially expressed in stem vs non-stem cell profiles in leukemic 
and normal samples were found in human and mouse experiments. 4 common 
SRAS pathways were identified. b) The SRAS pathprint scores of AML patients 
is significantly associated with survival. c) A single pathway of interest is 
highlighted, the overall PGCL2 module is upregulated in normal and cancer stem 
cells but individual genes differ between species. This pathway is strongly 
associated with survival (please see Additional file 13). 
 
Additional data files 
 
Additional file 1: Table listing platforms covered by Pathprint. 
Format: XLS 
 
Additional file 2: Table listing pathway sources, retrieval dates, URLs, and 
the top GO term that is enriched in each pathway (hypergeometric 
distribution p-value). 
Format: XLS 
 
Additional data 3: Table of the overlap in the genes covered by each gene 
set resource across in Pathprint (human pathways). 
Format: XLS 
 
Additional file 4, Supplementary Figure 1: Benchmarking and threshold 
optimization: Benchmarking based on the tissue dataset (above) and brain-
subtypes (below).  
a), d) Mean error rate based on 10 repeats of a 5-fold cross-validation over a 
range of POE thresholds. Error bars indicate -/+ 1 std.dev. The black line 
indicates the ratio for the unthresholded POE matrix, and the red for the barcode, 
dashed lines indicate -/+ 1 std.dev. b,d) Intra-cluster vs. inter-cluster variance 
ratio, over a range of POE thresholds dashed line indicates the ratio for the 
unthresholded POE matrix. c,f) Mean average precision over a range of POE 
thresholds for the pathprint (black circles) and a pathprint build on random gene 
sets of equivalent size distribution (blue circles). Solid lines indicate the mean 
average precision for Barcode (blue), Spearman correlation (green) and the 
unthresholded pathprint (red) N.B. barcode or gene expression correlation data 
were not calculated for the brain-subtype dataset 
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Additional file 5, Supplementary Figure 2: Precision-recall curves across the 
full set of GEO samples and distribution of distances of GEO samples from 
each tissue pathprint: (a) Precision-recall curves for each of the tissues across 
the pathprint-mapped GEO database; brain (red), kidney (yellow), liver (green), 
lung (cyan), skeletal muscle (blue), spleen (magenta). (b) Precision curves for 
each of the tissues across the pathprint-mapped GEO database (red, right axis) 
and histogram of distance of samples in the pathprint-mapped GEO database 
from each tissue consensus pathprint (black, left axis). Distance scales between 
0 (all pathway scores matched) to 1 (all pathway scores mis-matched, i.e. 1 vs -
1) (c) Estimated p-values: A p-value was assigned to every sample in the GEO 
pathprint matrix to assess the likelihood of association with the consensus 
pathprint for each tissue. The plots the relationship between this p-value and the 
precision (i.e. the proportion correctly matched to each tissue), as determined 
from the GEO metadata, when samples are ranked according to p-value. 
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Additional file 6: Table of the top R. norvegicus, D. rerio, D. melanogaster 
and C. elegans D.rerio matching arrays to human/mouse brain and liver 
samples. 
Format: XLS 
 
Additional file 7: Table listing the pathways in the pluripotent consensus 
pathprint. 
Format: XLS 
 
Additional file 8, Supplementary Figure 3: ES differentiation timecourse a) 
Distance from the embryonic stem cell pathprint signature of two mouse 
embryonic stem cell lines, J1 and R1, differentiating to embryoid bodies. The 
data were obtained from GEO accessions GSE2972 (J1) and GSE3749 (R1). b) 
Heatmap of pathways in the ES pathprint signature that vary over both 
differentiation timecourses (blue = -1, white = 0, red = +1). The column labeled 
ES denotes the ES pathprint signature. 
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Additional file 9: Table listing the pluripotent seed arrays and top arrays 
matching the pluripotent consensus pathprint. 
Format: XLS 
 
Additional file 10, Supplementary Figure 4: Combined human and mouse 
blood lineage tree: Pathway heatmap based on shared informative pathways 
that resolve trees b) and c) in Figure 2. 
Format: PDF 
 
Additional file 11, Supplementary Figure 5: Pathway-based survival analysis 
(a) Kaplan Meier curves of patients in 4 independent AML clinical datasets stratified by expression of common mouse and human SRAS pathways; 
Translation Factors (Wikipathways), GPCRs, Class B Secretin-like 
(Wikipathways), PLCG2 (Static Module), and RAN (Static Module). The red and 
blue lines indicates high and low pathprint scores respectively (b) P-value of 
Kaplan Meier estimator of patients stratified by expression of common mouse 
and human SRAS pathways in 4 independent clinical datasets, relative to a 
background of randomly selected pathways from the full pathprint set, (c) 
common genes relative to a background of randomly selected genes from 
expression chip (only single dataset shown), and (d) common SRAS pathways 
relative to a background of randomly selected human SRAS pathways. A red dot 
indicates the p-value, the grey cone is a bean plot representing the distribution of 
p-values from 1000 randomly selected sets of pathways or genes. The blue line 
indicates a p-value of 0.05 
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Additional file 12, Supplementary Figure 6: Pathway-based survival analysis 
by species Kaplan Meier curves of AML patients stratified by expression of 
common human and mouse (a), human (b), and mouse (c) SRAS pathways in 4 
independent clinical datasets. The red and blue lines indicate high and low 
pathprint scores respectively. 
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Additional file 13, Supplementary Figure 7: The PGLC2 module a) The protein-
protein interaction network of a single human/mouse common SRAS pathway - 
the PGLC2 module. Node color represents fold change in the combined 
leukemic/normal blood dataset (expression in normal and leukemia stem cells / 
expression in progenitor cells). b) The pathprint score of this single pathway in 
AML patients is associated with survival in 4 independent clinical datasets (red = 
+1, yellow = 0, blue = -1) 
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